CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞在多发性骨髓瘤治疗中的应用
英文原题：Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
查看英文原题
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞（CAR-Ts）代表了利用免疫系统对抗恶性肿瘤的另一种强大方式。事实上，在多发性骨髓瘤中，针对B细胞成熟抗原的疗法在疾病后期治疗线中展现出的高缓解率和缓解持续时间，已促成2项美国食品药品监督管理局（FDA）药物批准，并为该药物类别的开发打开了大门。本综述旨在提供关于2款FDA获批产品的最新信息，总结最有前景的下一代多发性骨髓瘤CAR-Ts的数据，并概述该领域当前的挑战及潜在解决方案。
展开英文摘要原文
Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class.
This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.
论文信息
- 作者
- Hasanali ZS、Razzo B、Susanibar-Adaniya SP、Garfall AL、Stadtmauer EA、Cohen AD
- 第一作者单位
- Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.United States
- 通讯作者单位
- Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA. Electronic address: Adam.Cohen@pennmedicine.upenn.edu.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Hematology/oncology clinics of North America2024 Apr
- 原文标识
- PubMed 38158242 · DOI 10.1016/j.hoc.2023.12.004
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →